IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
License Holder: Amgen Europe B.V., Israel Branch.
For full details please refer to the PI as approved by the IL MoH

LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an approved test, with no EGFR, ALK or ROS1 aberrations, and is:• locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or• metastatic.

LIBTAYO in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations and is:• locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or• metastatic.

For full details please refer to the PI as approved by the IL MoH

Encorafenib is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma with a BRAF V600E mutation, as detected by an approved test.

Binimetinib is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) adenocarcinoma with a BRAF V600E mutation, as detected by an approved test.

For full details please refer to the PI as approved by the IL MoH

LUMYKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an approved test, who have received at least one prior systemic therapy.

License Holder: Amgen Europe B.V., Israel Branch.

For full details please refer to the PI as approved by the IL MoH